Skip to main content
Top
Published in: Infection 4/2023

29-12-2022 | Anosmia | Image

Olfactory cleft infection revealed by anosmia

Authors: Maxime Fieux, Camille Kolenda, Alexis Trecourt, Stéphane Tringali

Published in: Infection | Issue 4/2023

Login to get access

Excerpt

A 24-year-old oenologist was admitted for anosmia following SARS-CoV-2 infection confirmed by RT-PCR. He had no particular medical history and was not taking any medications long-term. Nasofibroscopic examination revealed a normal left nasal fossa and edema of the right olfactory cleft (OC) with a polypoid aspect (Fig. 1A, arrow). Severe hyposmia was confirmed with a total score of 14/32 with the European Test of Olfactory Capabilities [1] (E.T.O.C). Computed tomography of the skull base revealed an OC mass (Fig. 1B, arrow). Contrast-enhanced T2-weighted magnetic resonance imaging revealed a dark signal in the OC with a high signal in surrounding soft tissue, indicating hypertrophic mucosal walls (Fig. 1C, arrow). Endoscopic right sinus surgery was performed to remove the abscess, free the OC and perform biopsies [2]. Histological analysis confirmed the presence of filamentous bacteria grains around a sinusal foreign plant body, characteristic of Actinomyces (Grocott positive, Gram positive and Ziehl negative) (Fig. 2), DNA extraction was performed followed by an Actinomyces-specific PCR and the final integrated histo-molecular diagnosis was a chronic sinusitis due to Actinomyces odontolyticus/meyeri also known as Actinomycosis. The patient was discharged to home and received an oral course of amoxicillin clavulanic acid for 10 days (1 g three times a day). At 1 month postoperatively, the patient had already experienced recovery of his olfactory capabilities (ETOC total score of 24/32 (mild hyposmia)). Actinomycosis is a chronic infection caused by anaerobic pseudofilamentous bacteria or fungi. Considering the lack of information about this disease in the paranasal sinuses, especially in nonendemic areas, it is of high importance to enhance the awareness of clinicians, especially with infections varying widely in presentation and extent of disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Joussain P, Bessy M, Faure F, et al. Application of the European test of olfactory capabilities in patients with olfactory impairment. Eur Arch Otorhinolaryngol. 2016;273:381–90.CrossRefPubMed Joussain P, Bessy M, Faure F, et al. Application of the European test of olfactory capabilities in patients with olfactory impairment. Eur Arch Otorhinolaryngol. 2016;273:381–90.CrossRefPubMed
2.
go back to reference Jiang R-S, Liang K-L. The effect of endoscopic olfactory cleft opening on obstructed olfactory cleft disease. Int J Otolaryngol. 2020;2020:8073726. Jiang R-S, Liang K-L. The effect of endoscopic olfactory cleft opening on obstructed olfactory cleft disease. Int J Otolaryngol. 2020;2020:8073726.
Metadata
Title
Olfactory cleft infection revealed by anosmia
Authors
Maxime Fieux
Camille Kolenda
Alexis Trecourt
Stéphane Tringali
Publication date
29-12-2022
Publisher
Springer Berlin Heidelberg
Keyword
Anosmia
Published in
Infection / Issue 4/2023
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-022-01974-w

Other articles of this Issue 4/2023

Infection 4/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.